These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27534575)

  • 1. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
    Ferreira AR; Alho I; Shan N; Matias M; Faria M; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
    Oncologist; 2016 Dec; 21(12):1418-1426. PubMed ID: 27534575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
    Lipton A; Cook RJ; Major P; Smith MR; Coleman RE
    Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
    Lipton A; Cook R; Saad F; Major P; Garnero P; Terpos E; Brown JE; Coleman RE
    Cancer; 2008 Jul; 113(1):193-201. PubMed ID: 18459173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
    Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.
    Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A
    J Clin Oncol; 2002 Feb; 20(3):850-6. PubMed ID: 11821470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases.
    Shizuku M; Shibata M; Okumura M; Takeuchi D; Kikumori T; Mizuno Y
    Breast Cancer; 2020 Nov; 27(6):1065-1071. PubMed ID: 32415556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
    Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
    Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
    J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
    Generali D; Dovio A; Tampellini M; Tucci M; Tedoldi S; Torta M; Bonardi S; Allevi G; Aguggini S; Milani M; Harris AL; Bottini A; Dogliotti L; Angeli A; Berruti A
    Br J Cancer; 2008 Jun; 98(11):1753-8. PubMed ID: 18506177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
    Zhao X; Xu X; Zhang Q; Jia Z; Sun S; Zhang J; Wang B; Wang Z; Hu X
    BMC Cancer; 2011 Sep; 11():403. PubMed ID: 21936956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
    Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
    Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.
    Gui Q; Xu C; Li D; Zhuang L; Xia S; Yu S
    Mol Med Rep; 2015 Sep; 12(3):4243-4249. PubMed ID: 26081451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.
    Mercatali L; Ricci M; Scarpi E; Serra P; Fabbri F; Ricci R; Liverani C; Zanoni M; Zoli W; Maltoni R; Gunelli E; Amadori D; Ibrahim T
    Int J Mol Sci; 2013 May; 14(6):10683-93. PubMed ID: 23702841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.
    Orita Y; Sugitani I; Takao S; Toda K; Manabe J; Miyata S
    Ann Surg Oncol; 2015 Nov; 22(12):4008-13. PubMed ID: 25762482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer: A Prospective Study.
    Tamiya M; Tokunaga S; Okada H; Suzuki H; Sasada S; Okamoto N; Morishita N; Shiroyama T; Otsuka T; Miyamoto N; Taira K; Daga H; Takeda K; Hirashima T
    Anticancer Res; 2015 Jul; 35(7):3987-93. PubMed ID: 26124346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
    Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
    J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X; Xu X; Guo L; Ragaz J; Guo H; Wu J; Shao Z; Zhu J; Guo X; Chen J; Zhu B; Wang Z; Hu X
    Breast Cancer Res Treat; 2010 Dec; 124(3):733-43. PubMed ID: 20882405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases.
    Zhao YY; Xue C; Hou X; Liao H; Li S; Zhao HY; Huang Y; Chen LK; Xu F; Liu JL; Zhang L
    Eur J Cancer; 2011 Apr; 47(6):848-53. PubMed ID: 21256000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.